Cancer Stem Cells and Pluripotency

Sripathi M. Sureban1,2,3*, Jeremy J. Johnson1,4 and Courtney W. Houchen1,2,3*

1Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
2Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA
3The Peggy and Charles Stephenson Oklahoma Cancer Institute, Oklahoma City, Oklahoma, USA
4Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

Keywords: Cancer stem cell; Induced pluripotent stem cell; Pluripotency

Cancer stem cells

Determining the functional roles of cancer stem cells (CSCs) and epithelial to mesenchymal transition (EMT) in carcinogenesis and tumorigenesis are pivotal topics in cancer biology research in general and pancreatic cancer in particular. Several publications, including ours, have demonstrated that CSCs and EMT function in tandem, ultimately leading to cancer progression and metastasis [1]. This has been demonstrated in breast, pancreas, and colorectal cancers and likely occurs in all types of cancers. A pressing issue in the field of CSC and EMT research is that of pancreatic adenocarcinoma (PDAC), as it has the worst prognosis of any major malignancy with a 3% 5-year survival rate [2]. Major obstacles in treating pancreatic cancer include delayed diagnosis, extensive local tumor invasion, and early metastasis. CSCs, or cancer initiating cells (CICs), represent approximately 1% to 5% of the tumor, and are capable of unlimited self-renewal, and are often resistant to chemotherapy and radiation therapy [3]. This may explain why these treatments do not cure or prevent recurrence of PDAC [4,5]. Improving survival for all types of cancer likely hinges on the identification and eradication of CSCs. The existence of CSCs was first demonstrated in acute myelogenous leukemia [6] and subsequently verified in breast [7], pancreatic [8], and brain tumors [9-11]. The CD133+ subpopulations from brain tumors can initiate clonally derived neurospheres in vitro showing self-renewal, differentiation, and proliferative characteristics similar to normal brain stem cells [9-11]. In a recent study, a subpopulation of CD44+ CD24+ ESA+ cells derived from primary human pancreatic adenocarcinoma CSCs [8] were implanted in immunocompromised mice and resulted in enhanced tumorigenic potential. We have recently demonstrated that doublecortin and CAM kinase-like-1 (DCAMKL-1) is a pancreatic stem cell marker that is upregulated in pancreatic cancer and may be a marker of CSCs [1,12].

It has been hypothesized that CSCs and cancer cells arise from stem cells due to external injury or mutation in the genome. These stem cells can be distinguished from other cells by two characteristics: (a) self-renewability and (b) pluripotency. Pluripotency is the ability of a cell to differentiate into any cell type and is a unique characteristic of embryonic stem cells (ESCs). Pluripotency transcription factors OCT4, SOX2, Nanog, and KLF4 form regulatory networks and influence a wide spectrum of downstream genes [13]. Overexpression of these factors can dedifferentiate human and mouse somatic cells into induced pluripotent stem cells (iPSCs). This indicates that CSCs and iPSCs behave in a similar manner.

There are several links between CSCs and iPSCs, including the p53 gene. p53 is a tumor suppressor gene and is a master regulator in cancer prevention. Furthermore, it has been demonstrated that p53 prevents pluripotency. Blocking the p53 pathway results in improved efficiency of transformation of differentiated cells into iPSCs. Also, p53 is mutated in various cancers and overexpression in cancer cells leads to apoptosis. p53 is not the only cancer-related factor important for the creation of iPSCs. The reprogramming factors OCT4, SOX2, Nanog, KLF4, c-Myc, and Lin28 have also been suggested to be oncogenes and may be implicated in the generation of various cancers. OCT4 is overexpressed in CD133+ lung cancer stem-like cells and plays a crucial role in maintaining cancer stemness and chemoresistant properties [14]. OCT4 has also been demonstrated to play a major role in liver [15], non-small cell lung [16], and gastric [17] cancer initiation and progression. Over-expression of OCT4 and Nanog has been observed in human pancreatic metastatic ducts, and that increased OCT4 expression precedes Ras mutation. These data suggest that OCT4 and Nanog are associated with early stage pancreatic carcinogenesis and play an important role in cancer progression [18]. SOX2 is up-regulated in early pancreatic cancer lesions [19] and in a majority of advanced tumors [20]. In the MCF-7 breast cancer cell line, SOX2 over-expression stimulated anchorage independent growth and induced tumor growth in mice, while its knockdown produced converse effects. [21]. The KLF4a gene is upregulated in aggressive human pancreatic cancer cells and tumor tissues. Overexpression of KLF4a results in pancreatic tumor growth in mice [22]. All these data taken together indicate that factors responsible for reprogramming cells to iPSCs play a major role in CSCs. These data suggest that iPSCs are analogous to ‘man-made CSCs’.

Multiple authors have shown that these transcription factors are regulated, at least in part, by microRNAs (miRNAs). miRNAs are non-protein-coding RNA molecules that regulate gene expression and play an important role in iPSCs, CSCs, and cancer. mir-145 specifically inhibits the aforementioned pluripotency factors by binding the 3’ untranslated mRNA region, leading to inhibition of ESCs, self renewal, and induction of differentiation [13]. Furthermore, loss of mir-145 impairs differentiation and elevates OCT4, SOX2, and KLF4. Additionally, it has been demonstrated that the mir-145 promoter is bound and repressed by OCT4 in ESCs. This indicates (a) the existence of a direct link between the core reprogramming factors and miR-145, and (b) the presence of a double-negative feedback loop involving OCT4, SOX2, KLF4, and mir-145 [13]. mir-145 demonstrates tumor suppressor properties and is downregulated in cancer tissue/specimens. Evidence supporting that loss of mir-145 (mir-143/145 cluster) is observed in KRAS mutated pancreatic cancers, and restoration of these miRNAs abrogates tumorigenesis. Furthermore, Ras-responsive element binding protein 1 represses...
miR-143/miR-145 promoter activity, indicating that repression is an early event in pancreatic cancer initiation and progression [23]. Additionally, it has been demonstrated that miR-143/145 is associated with bone metastasis of prostate cancer and involved in regulation of EMT. Ectopic expression of miR-143/145 results in repressed metastasis and increased adhesion of pancreatic cancer cells [24]. This evidence indicates that miR-145 is a master regulator of iPSC factors in ESCs and CSCs, and may play an important role in inhibition of pancreatic cancer initiation, progression, and EMT.

Understanding the miRNA pathways and the molecular mechanisms that control them is paramount to the elucidation of CSC self-renewal and pluripotency. Furthermore, understanding the connections between iPSCs and CSCs has significant potential for improving cancer treatment modalities, as iPSCs (reprogrammed adult differentiated cells) can be differentiated into specific or desired cell types. It may be assumed that CSCs are reprogrammed adult differentiated cells and may be able to differentiate into non-malignant cell types. We predict that miR-145 has great promise as a potential drug target as it suppresses pancreatic cancer initiation, progression, and EMT by repressing key pluripotency factors.

**Funding**

This work was supported by the grants from National Institute of Health and National Cancer Institute (NCI) CA137482 and from the Oklahoma Center for Adult Stem Cell Research (OCASCR) to CWH.

**References**

1. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, et al. (2011) DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71: 2328-2338.
2. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, et al. (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45: 823-830.
3. Dlein M, and Clarke MF (2006) Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-1757.
4. Hermann PC, Huber SL, Herlter T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
5. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314.
6. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
8. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
9. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumours. Oncogene 23: 7267-7273.
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumours. Cancer Res 63: 5821-5829.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
12. May R, Sureban SM, Lightfoot SA, Hoskins AB, Brackett DJ, et al. (2010) Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol 299: G303-310.
13. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647-658.
14. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637.
15. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, et al. (2010) Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-APC-binding cassette G2 pathway. Hepatology 52: 528-539.
16. Karoubi G, Gugger M, Schmid R, Dutly A (2009) OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Int J Cardiovasc Thorac Surg 8: 393-397.
17. Chen Z, Xu W, Qian H, Zhu W, Bu XF, et al. (2009) Oct4, a novel marker for human gastric cancer. J Surg Oncol 99: 414-419.
18. Wen J, Park JY, Park KH, Chung HW, Bang S, et al. (2010) Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 39: 622-626.
19. Prasad NB, Biankin AV, Fukushima N, Malta A, Dhara S, et al. (2005) Gene expression profiles in pancreatic intrapathelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 65: 1619-1626.
20. Sanada Y, Yoshioka K, Ohara M, Oeda M, Konishi K, et al. (2006) Identification of human brain tumour initiating cells. Nature 432: 396-401.
21. Chen Y, Shi L, Zhang L, Li R, Liang J, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17976.
22. Wei D, Wang L, Kanai M, Jia Z, Le X, et al. (2010) KLF4alpha up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology 139: 2135-2145.
23. Kent OA, Chivukula RR, Mullendore M, Westzel EA, Feldmann G, et al. (2010) Repression of the microRNA-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 24: 2754-2759.
24. Peng X, Guo W, Liu T, Wang X, Tu X, et al. (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6: e20341.